Comparison of efficacy and safety of oral agents for the treatment of relapsing–remitting multiple sclerosis

In the therapeutic scenario of disease-modifying therapies for relapsing–remitting multiple sclerosis, the introduction of oral agents, starting in 2010 with fingolimod, has been a huge step forward in therapeutic options due to the easier administration route. Three oral drugs fingolimod, terifluno...

Descripción completa

Detalles Bibliográficos
Autores principales: Guarnera, Cristina, Bramanti, Placido, Mazzon, Emanuela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546180/
https://www.ncbi.nlm.nih.gov/pubmed/28814828
http://dx.doi.org/10.2147/DDDT.S137572

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546180/
https://www.ncbi.nlm.nih.gov/pubmed/28814828
http://dx.doi.org/10.2147/DDDT.S137572

Ejemplares similares